Paul Hastings LLP advised Xoma Corporation on the deal. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator announced its multi-license and milestone monetization transaction with Viracta Therapeutics....
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here